NDA 221276 · Glaxosmithkline
Hibsago
Bepirovirsen Sodium · Subcutaneous
NovelPriority reviewCDER novel approval, Oct 20, 2026: To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Oct 20, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
13
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ON-TREATMENT HEPATIC FLARES AND THROMBOCYTOPENIA On-Treatment Hepatic Flares HIBSAGO may cause on-treatment hepatic flares with increases in ALT of >20-40x ULN associated with decline in HBsAg. Some cases were associated with hyperbilirubinemia. Most occurred in the first 12 weeks of treatment and resolved when treatment was interrupted or permanently discontinued [see Warnings and Precautions ( 5.1 ), Adverse Reactions ( 6.1 )] . ALT and total bilirubin must be measured prior to initiation of HIBSAGO and frequently monitored during treatment [see Dosage and Administration ( 2.4 ), Warnings and Precautions ( 5.1 )] . Do not initiate HIBSAGO in patients with evidence of acute hepatic impairment or cirrhosis [see Contraindications ( 4 )] . Interruption of treatment, followed by reducing the dose or discontinuation of HIBSAGO, may be necessary based on the results of liver...
What it is approved for
From the label in effect Oct 20, 2026.
HIBSAGO is indicated in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic hepatitis B virus (HBV) infection in adult patients without cirrhosis: • who have been on NrtI therapy for at least 6 months and have suppressed HBV deoxyribonucleic acid (DNA), and • who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test [see Dosage and Administration ( 2.2 )] . HIBSAGO is a hepatitis B virus (HBV) mRNA-directed antisense oligonucleotide (ASO) indicated in combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic HBV infection in adult patients without cirrhosis: • who have been on NrtI therapy for at least 6 months and have suppressed HBV deoxyribonucleic acid (DNA), and • who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test. ( 2.2 )
Mechanism: HIBSAGO is an antiviral drug against HBV [see Microbiology ( 12.4 )] .
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 20, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelMedication Guide
1 products under this application
- HIBSAGO · BEPIROVIRSEN SODIUM EQ 150MG BASE/ML (EQ 150MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Bepirovirsen" as an intervention, any sponsor and status, largest first.
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05630807 · 981 participants · Start Dec 7, 2022 · Primary completion Nov 11, 2025
Drug: Bepirovirsen · For: Chronic Hepatitis B; Hepatitis B, Chronic
Sites: Chandler, Arizona; Davis, California; Los Angeles, California · 177 sites in all
- Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT05630820 · 857 participants · Start Dec 6, 2022 · Primary completion Nov 3, 2025
Drug: Bepirovirsen · For: Chronic Hepatitis B; Hepatitis B, Chronic
Sites: Centreville, Alabama; Los Angeles, California; San Francisco, California · 171 sites in all
- Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)Active, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT04954859 · 366 participants · Start Dec 14, 2021 · Primary completion Jan 24, 2029
Drug: Bepirovirsen; Placebo · For: Hepatitis B
Sites: Sacramento, California; San Jose, California; Colorado Springs, Colorado · 161 sites in all
- B-Ensure: Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study ParticipantsNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07908459 · 303 participants (planned) · Start Dec 3, 2026 · Primary completion Dec 3, 2030
Drug: Bepirovirsen · For: Hepatitis B
- A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06537414 · 283 participants · Start Nov 11, 2024 · Primary completion May 31, 2027
Drug: Daplusiran/Tomligisiran Dose Level 1; Daplusiran/Tomligisiran Dose Level 2 and 2 more · For: Chronic Hepatitis B Virus Infection; Hepatitis B
Sites: San Francisco, California; San Jose, California; Minneapolis, Minnesota · 80 sites in all
GlaxoSmithKlineGSK (GSK)
NCT05276297 · 174 participants · Start Mar 22, 2022 · Primary completion Aug 5, 2025
Drug: GSK3228836; GSK3528869A and 1 more · For: Hepatitis B, Chronic
Sites: Edegem, Belgium; Sliven, Bulgaria; Sofia, Bulgaria · 51 sites in all
- A Study to Evaluate the Relative Bioavailability of Subcutaneous Bepirovirsen When Delivered From a Vial or Prefilled Syringe Fitted With a Safety Syringe Device in Healthy Adult ParticipantsPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06058390 · 160 participants · Start Oct 4, 2023 · Primary completion May 3, 2024
Drug: Bepirovirsen · For: Hepatitis B
Sites: Las Vegas, Nevada; Austin, Texas
- Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)Pivotal-lookingActive, not recruiting
GlaxoSmithKlineGSK (GSK)
NCT06497504 · 153 participants · Start Sep 17, 2024 · Primary completion Apr 22, 2027
Drug: Bepirovirsen; Placebo · For: Hepatitis B
Sites: Bakersfield, California; San Francisco, California; Orlando, Florida · 51 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.
Hou J, Lim SG, Buti M, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection.
Yuen MF, Lim SG, Plesniak R, et al. · N Engl J Med 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B.
Buti M, Heo J, Tanaka Y, et al. · J Hepatol 2025 · Randomized Controlled Trial, Clinical Trial, Phase II
- Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial.
Yuen MF, Heo J, Jang JW, et al. · Nat Med 2021 · Clinical Trial, Phase II, Randomized Controlled Trial
- Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses.
Han K, Theodore D, McMullen G, et al. · Clin Pharmacol Drug Dev 2022 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- B-Clear Phase 2b Study Design: Establishing the Efficacy and Safety of Bepirovirsen in Patients with Chronic Hepatitis B Virus Infection.
Cremer J, Elston R, Campbell FM, et al. · Adv Ther 2023 · Randomized Controlled Trial, Multicenter Study
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.